Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11718471 | 0.84 | PLA2G2A (0.44) | RARBNR5A1TP53TSHRPLA2G4B | |
| SCHEMBL15503349 | 0.83 | RARB (0.49) | RARBCYP3A4CYP2D6NR5A1TP53 | |
| SCHEMBL5640190 | 0.82 | LSS (0.56) | CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3071049 | 0.79 | ALDH1A1 (0.61) | RARBCYP3A4CYP2D6NR5A1TP53 | |
| SCHEMBL3086009 | 0.79 | ALDH1A1 (0.61) | RARBCYP3A4CYP2D6NR5A1TP53 | |
| SCHEMBL7289971 | 0.79 | ALDH1A1 (0.61) | RARBCYP3A4CYP2D6NR5A1TP53 | |
| SCHEMBL2123631 | 0.79 | ALDH1A1 (0.61) | RARBCYP3A4CYP2D6NR5A1TP53 | |
| SCHEMBL15503241 | 0.79 | RARB (0.50) | RARBCYP3A4CYP2D6NR5A1TP53 | |
| SCHEMBL15177390 | 0.78 | RARB (0.57) | RARBCYP3A4CYP2D6NR5A1TP53 | |
| SCHEMBL2491618 | 0.78 | RARB (0.64) | RARBTP53TSHRPLA2G4BPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2674437-A1 | Novel antibacterial agents for the treatment of GRAM positive infections | Cubist Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2379580-B1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARM INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2379580-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | Cubist Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010075215-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | RARB 4537/4885CYP3A4 4661/4885CYP2D6 4213/4885 |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | RARB 4537/4885CYP3A4 4661/4885CYP2D6 4213/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | RARB 4537/4885CYP3A4 4661/4885CYP2D6 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.